151 related articles for article (PubMed ID: 38845793)
1. Shaping tomorrow's vascular landscape with extracellular matrix stents.
James M; Sehgal VS
Eur Heart J Open; 2024 May; 4(3):oeae042. PubMed ID: 38845793
[No Abstract] [Full Text] [Related]
2. Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries.
Suna G; Wojakowski W; Lynch M; Barallobre-Barreiro J; Yin X; Mayr U; Baig F; Lu R; Fava M; Hayward R; Molenaar C; White SJ; Roleder T; Milewski KP; Gasior P; Buszman PP; Buszman P; Jahangiri M; Shanahan CM; Hill J; Mayr M
Circulation; 2018 Jan; 137(2):166-183. PubMed ID: 29030347
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
4. [Use of "Cypher" sirolimus-eluting stents in coronary heart disease patients with different types of coronary arterial lesions].
Belenkov IuN; Matchin IuG; Liakishev AA; Savchenko AP
Vestn Rentgenol Radiol; 2006; (3):4-12. PubMed ID: 17407958
[TBL] [Abstract][Full Text] [Related]
5. Covered-stent treatment of coronary aneurysm after drug-eluting stent placement: case report and literature review.
Bajaj S; Parikh R; Hamdan A; Bikkina M
Tex Heart Inst J; 2010; 37(4):449-54. PubMed ID: 20844620
[TBL] [Abstract][Full Text] [Related]
6. An Analysis of Cost-Effectiveness of Stents Used in the Treatment of Coronary Artery Disease.
Işıkçelik F; Ağırbaş İ; Tulunay Kaya C
Balkan Med J; 2019 Aug; 36(5):276-282. PubMed ID: 31290640
[TBL] [Abstract][Full Text] [Related]
7. Pathology of Endovascular Stents.
Nakamura K; Keating JH; Edelman ER
Interv Cardiol Clin; 2016 Jul; 5(3):391-403. PubMed ID: 28582036
[TBL] [Abstract][Full Text] [Related]
8. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
[TBL] [Abstract][Full Text] [Related]
9. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
10. Two-year outcome of Turkish patients treated with Zotarolimus versus Paclitaxel eluting stents in an unselected population with coronary artery disease in the real world: a prospective non-randomized registry in southern Turkey.
Ciçek D; Pekdemir H; Haberal C; Kalay N; Binici S; Altay H; Müderrisoğlu H
Int J Med Sci; 2011 Jan; 8(1):68-73. PubMed ID: 21234271
[TBL] [Abstract][Full Text] [Related]
11. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting stents for the treatment of coronary artery disease: A review of recent advances.
Hong SJ; Hong MK
Expert Opin Drug Deliv; 2022 Mar; 19(3):269-280. PubMed ID: 35180832
[TBL] [Abstract][Full Text] [Related]
13. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis.
Windecker S; Stortecky S; Stefanini GG; da Costa BR; Rutjes AW; Di Nisio M; Silletta MG; Maione A; Alfonso F; Clemmensen PM; Collet JP; Cremer J; Falk V; Filippatos G; Hamm C; Head S; Kappetein AP; Kastrati A; Knuuti J; Landmesser U; Laufer G; Neumann FJ; Richter D; Schauerte P; Sousa Uva M; Taggart DP; Torracca L; Valgimigli M; Wijns W; Witkowski A; Kolh P; Jüni P
BMJ; 2014 Jun; 348():g3859. PubMed ID: 24958153
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-eluting stents in coronary artery disease.
Nawarskas JJ; Osborn LA
Am J Health Syst Pharm; 2005 Nov; 62(21):2241-51. PubMed ID: 16239414
[TBL] [Abstract][Full Text] [Related]
15. Perioperative management of antiplatelet therapy in patients with drug-eluting stents.
Dimitrova G; Tulman DB; Bergese SD
HSR Proc Intensive Care Cardiovasc Anesth; 2012; 4(3):153-67. PubMed ID: 23439793
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of New Sirolimus-eluting Stent Models in a Preclinical Study.
Estévez-Loureiro R; Pérez de Prado A; Pérez-Martínez C; Cuellas-Ramón C; Regueiro-Purriños M; Gonzalo-Orden JM; López-Benito M; Molina-Crisol M; Duocastella-Codina L; Fernández-Vázquez F
Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1118-24. PubMed ID: 26206247
[TBL] [Abstract][Full Text] [Related]
17. Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(12):1-97. PubMed ID: 23074482
[TBL] [Abstract][Full Text] [Related]
18. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents.
Malenka DJ; Kaplan AV; Lucas FL; Sharp SM; Skinner JS
JAMA; 2008 Jun; 299(24):2868-76. PubMed ID: 18577731
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
